ABBV-291
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 05, 2025
A phase 1 study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting ADC in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
(ICML 2025)
- No abstract available
Clinical • P1 data • PK/PD data • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B
April 23, 2025
A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
(ASCO 2025)
- P1 | "Clinical Trial Registration Number: NCT06667687 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"
Clinical • P1 data • PK/PD data • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B
1 to 2
Of
2
Go to page
1